A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction

Karen Dugosh, Amanda Abraham, Brittany Seymour, Keli McLoyd, Mady Chalk, David Festinger, Karen Dugosh, Amanda Abraham, Brittany Seymour, Keli McLoyd, Mady Chalk, David Festinger

Abstract

Opioid use and overdose rates have risen to epidemic levels in the United States during the past decade. Fortunately, there are effective medications (ie, methadone, buprenorphine, and oral and injectable naltrexone) available for the treatment of opioid addiction. Each of these medications is approved for use in conjunction with psychosocial treatment; however, there is a dearth of empirical research on the optimal psychosocial interventions to use with these medications. In this systematic review, we outline and discuss the findings of 3 prominent prior reviews and 27 recent publications of empirical studies on this topic. The most widely studied psychosocial interventions examined in conjunction with medications for opioid addiction were contingency management and cognitive behavioral therapy, with the majority focusing on methadone treatment. The results generally support the efficacy of providing psychosocial interventions in combination with medications to treat opioid addictions, although the incremental utility varied across studies, outcomes, medications, and interventions. The review highlights significant gaps in the literature and provides areas for future research. Given the enormity of the current opioid problem in the United States, it is critical to gain a better understanding of the most effective ways to deliver psychosocial treatments in conjunction with these medications to improve the health and well-being of individuals suffering from opioid addiction.

Figures

FIGURE 1
FIGURE 1
Consort diagram of article selection.

References

    1. Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2008; 4: CD005031.
    1. Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2011; 9: CD005031.
    1. Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011; 10: CD004147.
    1. American Society of Addiction Medicine, American Society of Addiction Medicine Advancing Access to Addiction Medicine: Implications for Opioid Addiction Treatment. 2013.
    1. American Society of Addiction Medicine, American Society of Addiction Medicine The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. 2015.
    1. Brigham GS, Slesnick N, Winhusen TM, et al. A randomized pilot clinical trial to evaluate the efficacy of community reinforcement and family training for treatment retention (CRAFT-T) for improving outcomes for patients completing opioid detoxification. Drug Alcohol Depend 2014; 138:240–243.
    1. BUNAVAIL [package insert]. Raleigh, NC: BioDelivery Sciences International, Inc.; Last Revised September; 2014.
    1. Carpenter KM, Jiang H, Sullivan MA, et al. Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence. Psychol Addict Behav 2009; 23 1:47–55.
    1. Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry 2005; 162 8:1452–1460.
    1. Center for Behavioral Health Statistics and Quality, Center for Behavioral Health Statistics and Quality Behavioral Health Trends in the United States: Results From the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). 2015; . Accessed October 15, 2015.
    1. Centers for Disease Control and Prevention Vital sign: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep 2011; 60 43:1487–1492. . Accessed October 15, 2015.
    1. Centers for Disease Control and Prevention, Centers for Disease Control and Prevention New HIV infections in the United States. 2012.
    1. Chawarski MC, Zhou W, Schottenfeld RS. Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in wuhan, china: A pilot randomized clinical trial. Drug Alcohol Depend 2011; 115 3:237–239.
    1. Chen W, Hong Y, Zou X, et al. Effectiveness of prize-based contingency management in a methadone maintenance program in china. Drug Alcohol Depend 2013; 133 1:270–274.
    1. DeFulio A, Everly JJ, Leoutsakos J-MS, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend 2012; 120 (1–3):48–54.
    1. DEPADE [package insert]. Hazelwood, MO: Mallinckrodt, Inc.; Last Revised November 2014.
    1. Drummond DC, Perryman K. Psychosocial Interventions in Pharmacotherapy of Opioid Dependence: A Literature Review. London: St. George's University of London; 2007.
    1. Dunn KE, Defulio A, Everly JJ, et al. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Exp Clin Psychopharmacol 2013; 21 1:74–83.
    1. Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008; 165 2:179–187.
    1. Everly JJ, DeFulio A, Koffarnus MN, et al. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addiction 2011; 106 7:1309–1318.
    1. Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med 2013; 126 1:74.e11–77.e11.
    1. Gerra G, Saenz E, Busse A, et al. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35 2:483–489.
    1. Gruber VA, Delucchi KL, Kielstein A, et al. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend 2008; 94 (1–3):199–206.
    1. Gu J, Lau JT, Xu H, et al. A randomized controlled trial to evaluate the relative efficacy of the addition of a psycho-social intervention to standard-of-care services in reducing attrition and improving attendance among first-time users of methadone maintenance treatment in China. AIDS Behav 2013; 17 6:2002–2010.
    1. Hesse M, Pedersen MU. Easy-access services in low-threshold opiate agonist maintenance. Int J Ment Health Addict 2008; 6 3:316–324.
    1. Hser YI, Li J, Jiang H, et al. Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. Addiction 2011; 106 10:1801–1809.
    1. Jones CM, Logan J, Gladden RW, et al. Vital signs: demographic and substance use trends among heroin users: United states, 2002–2013. MMWR Morb Mortal Wkly Rep 2015; 64 26:719–725.
    1. Katz EC, Brown BS, Schwartz RP, et al. Transitioning opioid-dependent patients from detoxification to long-term treatment: efficacy of intensive role induction. Drug Alcohol Depend 2011; 117:24–30.
    1. Kelly SM, Schwartz RP, O’Grady KE, et al. Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trial. J Addict Med 2012; 6 2:145–152.
    1. Kidorf M, Brooner RK, Gandotra N, et al. Reinforcing integrated psychiatric service attendance in an opioid-agonist program: a randomized and controlled trial. Drug Alcohol Depend 2013; 133 1:30–36.
    1. Kouimtsidis C, Reynolds M, Coulton S, et al. How does cognitive behaviour therapy work with opioid-dependent clients? Results of the UKCBTMM study. Drugs: Educ Prev Polic 2012; 19 3:253–258.
    1. Ling W, Hillhouse M, Ang A, et al. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction 2013; 108 10:1788–1798.
    1. Marsch LA, Guarino H, Acosta M, et al. Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment. J Subst Abuse Treat 2014; 46 1:43–51.
    1. Methadone (Dolophine®) DOLOPHINE [package insert]. Columbus, OH: Roxane Laboratories, Inc.; Revised April 2015.
    1. Mitchell SG, Gryczynski J, Schwartz RP, et al. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (op) buprenorphine treatment for African Americans. Drug Alcohol Depend 2013; 128 3:222–229.
    1. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Ann Intern Med 2009; 151 4:264–269.
    1. Moore BA, Barry DT, Sullivan LE, et al. Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study. J Addict Med 2012; 6 3:205–211.
    1. Moore BA, Fazzino T, Barry DT, et al. The recovery line: a pilot trial of automated, telephone-based treatment for continued drug use in methadone maintenance. J Subst Abuse Treat 2013; 45 1:63–69.
    1. National Institute on Drug Abuse. Overdose death rates. 2015. Accessed October 15, 2015.
    1. Nunes EV, Rothenberg J, Sullivan MA, et al. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness. Am J Drug Alcohol Abuse 2006; 32:503–517.
    1. Nyamathi AM, Nandy K, Greengold B, et al. Effectiveness of intervention on improvement of drug use among methadone maintained adults. J Addict Dis 2011; 30 1:6–16.
    1. REVIA [package insert]. Pomona, NY: Barr Pharmaceuticals, Inc.; Revised December 2013.
    1. Ruetsch C, Tkacz J, McPherson TL, et al. The effect of telephonic patient support on treatment for opioid dependence: outcomes at one year follow-up. Addict Behav 2012; 37 5:686–689.
    1. Stotts AL, Green C, Masuda A, et al. A stage I pilot study of acceptance and commitment therapy for methadone detoxification. Drug Alcohol Depend 2012; 125 3:215–222.
    1. SUBOXONE [package insert]. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; Last Revised April 2014.
    1. SUBUTEX [package insert]. Montgomery, AL: Midlothian Laboratories; Last Revised September 2010.
    1. VIVITROL [package insert]. Waltham, MA: Alkermes, Inc.; Last Revised July 2013.
    1. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011; 68 12:1238–1246.
    1. ZUBSOLV [package insert]. Morristown, NJ: Orexo US, Inc.; Last Revised December 2014.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa